Behind Brexu-cel's Development in Relapsed/Refractory B-Cell ALL
In an interview with Targeted Oncology, Evandro D. Bezerra, MD, discusses brexucabtagene autoleucel for relapsed/refractory B-cell ALL.
Evandro D. Bezerra, MD, the Ohio State Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, discusses brexucabtagene autoleucel (Tecartus; brexu-cel) and how it has been developed for the treatment of patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) thus far.
Outcomes of brexu-cel in a broad real-world patient population of patients with R/R B-ALL were recently examined and showed to be consistent with findings from ZUMA-3 (NCT02614066), a trial which supported the FDA’s approval of the agent in 2021.
According to real-world findings, while there were differences between the patient populations in the real-world and clinical settings, the efficacy of brexu-cel in this real-world analysis was consistent with what was observed in the ZUMA-3 clinical trial.
Transcription:
0:09 | Brexu-cel is a CD19 [chimeric antigen receptor (CAR)] T-cell therapy for patients with relapsed/refractory B-cell ALL, and also other B-cell malignancies. [These] data show the real-world outcomes of brexu-cel since it was approved as a standard-of-care for this patient population. [These data] show that the brexu-cel is highly effective in the real-world setting, consistent with the data from the ZUMA-3 clinical trial, despite the significant difference between the patient populations in the ZUMA-3 clinical trial and the real-world population.
0:47 | The ZUMA-3 clinical trial was the pivotal trial that led to the approval of brexu-cel itself for relapsed/refractory B-cell ALL. On that trial, patients with relapsed/refractory B-cell ALL received brexu-cel itself, and they had high efficacy, with [complete response (CR)] rates of 71% and patients that responded had a median overall survival of 47 months.
REFERENCE:
Bezerra E, Itani T, Wudhikarn K, et al. Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) adult B-cell acute lymphoblastic leukemia (B-cell ALL): evidence from the CIBMTR registry. Blood. 2023;142(suppl 1):1029. doi:10.1182/blood-2023-174543
Revumenib for NPM1-Mutant AML Succeeds in Pivotal Trial
November 12th 2024In the phase 2 AUGMENT-101 trial, revumenib met its primary end point by achieving a complete remission or complete remission with partial blood count recovery in relapsed/refractory NPM1-mutant acute myeloid leukemia.
Read More
Uproleselan With Chemo Fails to Improve EFS in Older Patients With AML
November 2nd 2024A phase 2/3 study investigating uproleselan with standard 7+3 chemotherapy in newly diagnosed, older patients with acute myeloid leukemia did not achieve the primary end point of improved event-free survival.
Read More
